Genetic ablation of RIPK1 induces cell-cycle arrest and suppresses tumor growth in subcutaneous xenograft models, whereas pharmacological inhibition of RIPK1 with necrostatin-1 fails to restrict GBM cell expansion, suggesting that RIPK1 exerts oncogenic effects independent of its canonical necroptotic role. The gene discussed is RIPK1; the disease is neoplasm.